Hikma Ventures participates in a $20.5 million Series C round for Prognos

Hikma Ventures participates in a $20.5 million Series C round for Prognos

Amman, January 2018 – For its tenth consecutive year, Hikma Pharmaceuticals – the fast growing multinational pharmaceutical group – joins change-makers in its industry at the World Economic Forum (WEF) Annual Meeting in Davos, Switzerland. Featuring His Majesty King Abdullah II ibn Al Hussein and many distinguished speakers, the 48th Forum is taking place from 23 – 26 January, 2018, under the theme ‘Creating a Shared Future in a Fractured World’.

Through its partnership with the WEF as a Health Industry Associate, Hikma joins a network of health industry leaders, including global pharmaceutical companies, major health centers and hospitals, and top research and development centers and universities, to advance the state of global health.

Representing the Company at the Forum, Hikma Executive Vice Chairman, President and CEO of MENA and Emerging Markets, Mazen Darwazah, is a contributing speaker at an official session titled, ‘Going Digital in the Arab World.’ Also participating in the session are H.E. Sheikha Bodour bint Sultan bin Muhammad Al Qasimi, the Chairperson of the Sharjah Investment and Development Authority, Antonio Neri of Hewlett Packard Enterprise and Mohammed Alshaya of Alshaya Group, among others.

Darwazah also joins forces with the World Bank and the Red Cross (ICRC) in another session, ‘Rethinking Humanitarian Finance’, which tackles the vital issue of growing humanitarian needs, including forced displacement and how business, humanitarian and development parties can work together to deploy innovative financing solutions.

“Through its global operations, Hikma impacts communities around the world, working tirelessly to advance health in its locations in the MENA region, Europe and the US, as well as providing humanitarian assistance to those in need, including refugees,” said Darwazah. “Additionally, the field of e-health is one we have a keen interest in, as it presents numerous solutions to overcoming existing barriers. For this reason, Hikma Ventures – the corporate venture capital arm of Hikma Pharmaceuticals – is moving towards fostering a startup ecosystem by embracing a digital mindset and investing in upcoming digital health startups. This reaffirms Hikma’s mission of providing patients with better access to high-quality, affordable medicines in key therapeutic areas.”